Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Atara Biotherapeutics, Inc.
< Previous
1
2
3
4
Next >
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference
November 27, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
November 13, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress
November 12, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
November 05, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces $36 Million Registered Direct Offering
September 03, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
August 12, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 07, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
July 17, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
July 03, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
June 21, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
June 17, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
May 29, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
May 20, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
May 09, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
March 28, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
February 29, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
February 28, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
February 14, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
January 31, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces $15 Million Registered Direct Offering
January 08, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.